by MM360 Staff | Dec 12, 2025 | Publications
Diagnostics (Basel). 2025 Nov 21;15(23):2942. doi: 10.3390/diagnostics15232942. ABSTRACT After publication, the authors identified several errors in the manuscript, including inconsistencies between the manuscript’s reported results and the corresponding...
by MM360 Staff | Dec 12, 2025 | Publications
Cancers (Basel). 2025 Nov 21;17(23):3730. doi: 10.3390/cancers17233730. ABSTRACT BACKGROUND: Despite recent advances in the treatment of multiple myeloma (MM), the disease remains incurable. Agents targeting the programmed death-1 (PD-1) axis have become key...
by MM360 Staff | Dec 11, 2025 | Publications
Blood Cell Ther. 2025 Nov 25;8(4):301-310. doi: 10.31547/bct-2025-008. eCollection 2025 Nov 25. ABSTRACT BACKGROUND: The optimal conditioning dose of melphalan for autologous hematopoietic stem cell transplantation (AHSCT) in multiple myeloma remains a subject of...
by MM360 Staff | Dec 9, 2025 | Publications
Cureus. 2025 Dec 3;17(12):e98368. doi: 10.7759/cureus.98368. eCollection 2025 Dec. ABSTRACT Relapsed/refractory multiple myeloma (RRMM) remains a challenging condition with a need for more effective treatment options. There are ongoing clinical trials analyzing the...
by MM360 Staff | Dec 8, 2025 | Publications
Blood Cancer J. 2025 Dec 6;15(1):212. doi: 10.1038/s41408-025-01413-7. ABSTRACT Frontline therapy for transplant-ineligible newly diagnosed multiple myeloma (TI-NDMM) has advanced with anti-CD38 monoclonal antibody (mAb)-based regimens. Although quadruplet...
by MM360 Staff | Nov 18, 2025 | Publications
Front Oncol. 2025 Oct 30;15:1619115. doi: 10.3389/fonc.2025.1619115. eCollection 2025. ABSTRACT BACKGROUND: Triplet regimens, such as bortezomib-lenalidomide-dexamethasone (VRd) and bortezomib-melphalan-prednisone (VMP), were standard treatments for newly diagnosed...
